ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biotechnology

Noramco signs pact for biobased cannabidiol

by Michael McCoy
June 7, 2019 | APPEARED IN VOLUME 97, ISSUE 23

 

Noramco and Willow Biosciences have agreed to jointly develop a biosynthetic route to cannabidiol (CBD), a cannabinoid that is increasingly being formulated into foods and cosmetics. Noramco claims to be the leading producer of CBD via chemical synthesis; Willow was formed earlier this year through the merger of two companies with technology developed by scientists at Canadian universities. The partners say Willow’s yeast-based biosynthesis can yield CBD “at substantially lower costs compared to current methods.”

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment